Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Carcinoma 2ALK-positive Advanced NSCLC 2Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Brain Neoplasms 1Adenocarcinoma 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × brigatinib × Clear all
NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

University of Colorado, Denver

Phase 2 Terminated
1 enrolled 6 charts
CNSThoracic

Brain Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡